Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

qd herbs sdn. bhd. - soya bean powder; soya protein -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mission bell holdings pty ltd - soyal phospholipids; propionic acid - soluble concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - improve drift control | improve pesticide deposition | reduce alkaline hydrolysis | wetting agent (use as directed) | improve penetrating properties | improves chemical uptake | improves droplet deposition

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

opal australasia pty ltd - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - acidifying surfactant | improve drift control | penetrating surfactant | reduce alkaline hydrolysis | improves chemical uptake

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a), medium-chain triglycerides (unii: c9h2l21v7u) (medium-chain triglycerides - unii:c9h2l21v7u), olive oil (unii: 6uyk2w1w1e) (olive oil - unii:6uyk2w1w1e), fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - soybean oil 6 g in 100 ml - smoflipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (pn) when oral or enteral nutrition is not possible, insufficient, or contraindicated. use of smoflipid is contraindicated in patients with: - known hypersensitivity to fish, egg, soybean, peanut or any of the active or inactive ingredients in smoflipid [see warnings and precautions (5.3)] - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1,000 mg/dl) [see warnings and precautions (5.7)] risk summary administration of the recommended dose of smoflipid is not expected to cause major birth defects, miscarriage, or other adverse maternal or fetal outcomes. no animal reproduction studies have been conducted with smoflipid. there are risks to the fetus associated with severe malnutrition during pregnancy (see clinical considerations) . the estimated background risk of major birth defects and miscarriag

United States - English - NLM (National Library of Medicine)

baxter healthcare corp - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 10 g in 100 ml - intralipid® 10% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad. intralipid 10% is contraindicated in patients with: - disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. - known hypersensitivity to egg, soybean, peanut protein, or to any of the active ingredients or excipients of intralipid 10%. instruction for use - intralipid® 10% container

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 20 g in 100 ml - intralipid® 20% pharmacy bulk package is indicated for use in a pharmacy admixture program for the preparation of three-in-one or total nutrition admixtures (tnas) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and a source of essential fatty acids for prevention of efad. intralipid is contraindicated in patients with: - disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. - known hypersensitivity to egg, soybean, peanut protein, or to any of the active ingredients or excipients in intralipid 20%. intralipid 20% pharmacy bulk package is not intended for direct intravenous administration. diluting intralipid 20% to a 10% concentration with intravenous fluid such as normal saline or other diluents does not produce a dillition that is equivalent in composition to intralipid 10% i.v. fat emulsion, and such

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 20 g in 100 ml - intralipid® 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad. intralipid 20% is contraindicated in patients with: - disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. - known hypersensitivity to egg, soybean, peanut protein, or to any of the active ingredients or excipients in intralipid 20%. instruction for use - intralipid® 20% container

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 30 g in 100 ml - intralipid® 30% pharmacy bulk package is indicated for use in a pharmacy admixture program for the preparation of three-in-one or total nutrient admixtures (tnas) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad. intralipid is contraindicated in patients with: - disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. - known hypersensitivity to egg, soybean, peanut protein, or to any of the active ingredients or excipients in intralipid 30%. intralipid 30% pharmacy bulk package is not intended for direct intravenous administration. diluting intralipid 30% to a 10% or 20% concentration with an intravenous fluid such as normal saline or other diluent does not produce a dilution that is equivalent in composition to intralipid 10% or 20% i.v. fat

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 20 g in 100 ml - intralipid ®  20% pharmacy bulk package is indicated for use in a pharmacy admixture program for the preparation of three-inone or total nutrition admixtures (tnas) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and a source of essential fatty acids for prevention of efad. the administration of intralipid ® is contraindicated in patients with disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. intralipid ®  20% pharmacy bulk package is not intended for direct intravenous administration. diluting intralipid ®  20% to a 10% concentration with intravenous fluid such as normal saline or other diluents does not produce a dillition that is equivalent in composition to intralipid ® 10% i.v. fat emulsion, and such a dilution should not be given by dir

Australia - English - Department of Health (Therapeutic Goods Administration)

bio concepts pty ltd - soy phosphatidylserine-enriched soy lecithin powder -